Duloxetine in Breastfeeding
Duloxetine can be used during breastfeeding with infant monitoring, as it transfers into breast milk at very low levels (relative infant dose <1% of maternal weight-adjusted dose), though infants should be monitored for sedation, poor feeding, and inadequate weight gain.
Evidence from FDA Drug Label
The FDA label explicitly addresses duloxetine use during lactation 1. Key pharmacokinetic data from 6 lactating women taking 40 mg twice daily showed:
- Peak breast milk concentration occurs at median 3 hours post-dose
- Approximately 7 mcg/day passes into breast milk
- Estimated daily infant dose is approximately 2 mcg/kg/day
- This represents less than 1% of the maternal dose
The FDA specifically warns that there are reports of sedation, poor feeding, and poor weight gain in infants exposed to duloxetine through breast milk 1. The label recommends that infants exposed to duloxetine should be monitored for these specific adverse effects.
Supporting Research Evidence
Multiple studies confirm the low transfer into breast milk:
- A 2011 study demonstrated a cord/maternal serum ratio of 0.12 and relative infant dose of 0.81% 2
- A 2018 case series found relative infant doses of 0.2-0.4% with no adverse effects in exposed infants 3
- A 2008 pharmacokinetic study showed mean milk-to-plasma ratio of 0.25, with estimated infant dose of 0.14% of maternal dose 4
A 2014 review concluded that infant exposure to duloxetine in breast milk is less than 1% of the maternal weight-adjusted dose, suggesting duloxetine can be safely administered to breastfeeding women 5.
Clinical Approach
If duloxetine is necessary for maternal mental health:
Prioritize maternal treatment - The benefits of treating maternal depression/anxiety must be weighed against theoretical infant risks
Use the lowest effective maternal dose that maintains therapeutic benefit
Monitor the infant closely for:
- Sedation or excessive drowsiness
- Poor feeding or decreased appetite
- Inadequate weight gain
- Any behavioral changes
Consider timing of doses - Though not specifically studied for duloxetine, taking the dose immediately after breastfeeding or before the infant's longest sleep period may minimize infant exposure
Important Caveats
- Long-term neurodevelopmental outcomes have not been systematically studied in infants exposed to duloxetine via breast milk 6
- The FDA label emphasizes that "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for duloxetine" 1
- If the mother was successfully treated with duloxetine during pregnancy, continuing during breastfeeding maintains therapeutic continuity and avoids maternal relapse
Alternative Considerations
While duloxetine appears relatively safe, if an alternative SSRI is equally effective for the mother, sertraline or paroxetine may be preferred as they have more extensive safety data during lactation, with consistently low or undetectable infant plasma levels 7, 8. However, switching medications postpartum carries its own risks of maternal relapse.
The decision should prioritize effective maternal treatment while implementing appropriate infant monitoring protocols.